IMPAX Laboratories Postpones Third Quarter 2004 Financial Results Conference Call to Tuesday, November 9, 2004

November 03, 2004

HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 3, 2004--IMPAX Laboratories, Inc. (Nasdaq NM:IPXL) today announced that the Company has postponed its release of 2004 third quarter financial results to Tuesday, November 9, 2004 in order to allow its independent auditors more time to complete their review of the Company's third quarter financial statements, including the timing of certain customer credits on bupropion products marketed by a strategic partner. Results were originally scheduled to be announced on Thursday, November 4, 2004.

Management will host an investment conference call beginning at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) on November 9, 2004 to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (888) 803-7396 from the U.S., or for international callers, please dial (706) 634-1052.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the Company Web site for 14 days beginning November 9, 2004. A telephone replay will be available from 1:00 p.m. Eastern Time November 9 through 11:59 p.m. Eastern Time November 11, by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering conference ID number 1751374.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause IMPAX's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, IMPAX's ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX's ability to successfully develop and commercialize pharmaceutical products, IMPAX's reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX's filings with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and IMPAX undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

    CONTACT: IMPAX Laboratories, Inc.
             Barry R. Edwards, (215) 933-0323 Ext. 4360
             Larry Hsu, (510) 476-2000 Ext. 1111
             Cornel C. Spiegler, (215) 289-2220 Ext. 1706
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates, Inc.
             Kim Sutton Golodetz (
             (212) 838-3777
             Bruce Voss (
             (310) 691-7100

    SOURCE: IMPAX Laboratories, Inc.